Selected Publications

Lehrnbecher T, Robinson PD, Ammann RA, Fisher B, Patel P, Phillips R, Beauchemin MP, Carlesse F, Castagnola E, Davis BL, Elgarten CW, Groll AH, Haeusler GM, Koenig C, Santolaya ME, Tissing WJE, Wolf J, Alexander S, Hu H, Dupuis LL, Sung L.: Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update. J Clin Oncol Jan 2023.

Elgarten CW, Thompson JC, Angiolillo A, Chen Z, Conway S, Devidas M, Gupta S, Kairalla JA, McNeer JL, O'Brien MM, Rabin KR, Rau RE, Rheingold SR, Wang C, Wood C, Raetz EA, Loh ML, Alexander S, Miller TP.: Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer Nov 2022.

Molina JC, Li Y, Otto WR, Miller TP, Getz KD, Mccoubrey C, Ramos M, Krause E, Cao L, Gramatges MM, Rabin K, Scheurer M, Elgarten CW, Myers RM, Seif AE, Fisher BT, Shah NN, Aplenc R.: Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. Pediatr Blood Cancer Nov 2022.

Elgarten CW, Otto WR, Shenton L, Stein MT, Horowitz J, Aftandilian C, Arnold SD, Bona KO, Caywood E, Collier AB, Gramatges MM, Henry M, Lotterman C, Maloney K, Modi AJ, Mian A, Mody R, Morgan E, Raetz EA, Verma A, Winick N, Wilkes JJ, Yu JC, Aplenc R, Fisher BT, Getz KD.: Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. Infect Control Hosp Epidemiol Apr 2022.

Elgarten CW, Tanes C, Lee J-j, Danziger-Isakov LA, Grimley MS, Green MD, Michaels MG, Barnum JL, Ardura MI, Auletta JJ, Blumenstock J, Seif AE, Bittinger KL, Fisher BT: Early microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Pediatr Blood Cancer 69(1): e29384, October 2021.

Diorio C, Vardaro J, Wei Y, Mauro J, Croy C, Oranges KE, Reilly AF, Bailey LC, Jubelirer T, Elgarten CW*, Freedman JL.: Improving Guideline-Congruent Care for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Pediatric Oncology Patients. JCO Oncology Practice 18(3): e412-e419, October 2021.

Elgarten CW, Wood AC, Li Y, Alonzo TA, Brodersen LE, Gerbing RB, Getz KD, Huang YV, Loken M, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc R.: Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 68(12): e29281, October 2021 Notes: Epub ahead of print.

Hayes M, Newman AM, Boge CLK, Galetaki DM, Elgarten CW, Freedman JL, Olson TS, Fisher BT.: Incidence of CMV Infection and Disease and Adverse Events Associated with Antiviral Therapy in a Retrospective Cohort of Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital. J Pediatric Infect Dis Soc. 10(9): 910-918, Jul 2021.

Freedman JL, Elgarten CW, Rheingold SR: Management of Oncologic Emergencies. Lanzkowsky's Manual of Pediatric Hematology and Oncology 7th edition, June 2021 Notes: Chapter 31, in Lanzkowsky P, Lipton J and Fish J. (Ed.).

Triebwasser MP, Barrett DM, Bassiri H, Bunin N, Elgarten CW, Freedman J, Geera AS, Monos D, Lambert MP, Olson T, Seif AE, Paessler M, Petrosa W, Reilly AF, Romberg N, Sullivan KE, Quinn GZ, Behrens E, Teachey DT: Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatr Blood Cancer 68(7): e29026, March 2021.